论文部分内容阅读
目的探讨美沙拉嗪联合甲硝唑对溃疡性结肠炎患者炎症反应及疾病活动指数(DAI)的影响。方法选择2015年10月—2017年2月收治的溃疡性结肠炎患者78例,随机分为观察组与对照组,每组39例。对照组口服美沙拉嗪,观察组在此基础上加用甲硝唑。比较两组炎症反应、DAI评分与医师评估。计量资料比较采用t检验,以P<0.05为差异有统计学意义。结果治疗前,两组炎症反应、DAI评分及医师评估相比,差异无统计学意义(均P>0.05);治疗后,观察组IL-4水平高于对照组,IL-1β、TNF-α水平低于对照组,DAI评分及医师评估均低于对照组,差异有统计学意义(均P<0.05)。结论针对溃疡性结肠炎患者采用美沙拉嗪和甲硝唑联合治疗,能够有效控制炎症反应,优化DAI各项积分,促进患者恢复。
Objective To investigate the effect of mesalazine combined with metronidazole on inflammatory reaction and disease activity index (DAI) in patients with ulcerative colitis. Methods 78 patients with ulcerative colitis admitted from October 2015 to February 2017 were randomly divided into observation group and control group, 39 cases in each group. The control group oral mesalamine, the observation group on the basis of metronidazole. The inflammatory response, DAI score and physician evaluation were compared between the two groups. Measurement data were compared using t test to P <0.05 for the difference was statistically significant. Results Before treatment, there was no significant difference in inflammatory response, DAI score and physician evaluation between the two groups (all P> 0.05). After treatment, the level of IL-4 in the observation group was higher than that in the control group, IL-1β and TNF-α The level was lower than the control group, DAI score and physician evaluation were lower than the control group, the difference was statistically significant (P <0.05). Conclusion The combination of mesalazine and metronidazole in patients with ulcerative colitis can effectively control the inflammatory response, optimize the integration of DAI, and promote the recovery of patients.